The Vanderbilt University

1. Genentech, Inc. $739,581 70 payments
2. Pfizer Inc. $297,469 176 payments
3. Roche Products Limited $171,361 82 payments
4. Abbott Laboratories $99,045 28 payments
5. Fresenius Kabi USA, LLC $74,588 6 payments
6. Takeda Pharmaceuticals U.S.A., Inc. $50,140 29 payments
7. Biogen, Inc. $22,370 1 payment
8. Medivation Inc. $13,431 17 payments
9. Celgene Corporation $8,000 2 payments
10. Elekta, Inc. $5,548 1 payment

1. Phase II dose finding study in prodromal early manifest HD individuals $609,034 11 payments
2. A Phase 3 Randomized Efficacy and Safety Study of Enzalutamide Plus Leuprolide Enzalutamide Monotherapy and Placebo Plus Leuprolide in Men With Highrisk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy $184,961 68 payments
3. Prosper A Multinational Phase 3 Randomized Doubleblind Placebocontrolled Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castrationresistant Prostate Cancer $125,939 125 payments
4. Crohn S Disease Program Cohort 1 Induction Cohort II Maintenance $76,787 41 payments
5. Smof-018-Cp3 $74,588 6 payments
6. Crohn S Disease Program Ole $51,202 37 payments
7. An Open Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase II III Studies $45,027 25 payments
8. Trial to Evaluate the Efficacy and Safety of PRM 151 in Patients With Idiopathic Pulmonary Fibrosis $43,372 4 payments
9. AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial $30,366 6 payments
10. Hemodynamic Guided Monitoring in Heart Failure (HF) Trial $29,652 8 payments

1. Other $38,370 14 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.